Table 2 Demographic and clinical characteristics of RA patients according to BMI
Measurement | All | Normal weight | Preobese | Obese |
|---|---|---|---|---|
BMI 18.50–24.99 kg/m2 | BMI 25.00–29.99 kg/m2 | BMI ≥30.00 kg/m2 | ||
n = 64 | n = 21 | n = 21 | n = 22 | |
Female gender, n (%) | 60 (93.8) | 19 (90.5) | 20 (95.2) | 21 (95.5) |
Time of disease evolution, years | 5.34 ± 6.97 | 5.73 ± 8.95 | 5.06 ± 4.80 | 5.23 ± 6.78 |
Positive anti-CCP, n (%) | 46 (71.9) | 15 (71.4) | 13 (61.9) | 18 (81.8) |
Anti-CCP, U/Ml | 167.20 ± 305.49 | 179.03 ± 405.53 | 218.45 ± 338.76 | 107.00 ± 86.53 |
Positive RF, n (%) | 41 (65.1) | 13 (61.9) | 15 (71.4) | 13 (61.9) |
RF, UI/Ml | 79.39 ± 51.57 | 93.03 ± 43.26 | 79.65 ± 60.09 | 68.01 ± 47.61 |
ESR, mm/h | 21.27 ± 12.74 | 19.38 ± 9.82 | 17.10 ± 12.14 | 27.33 ± 14.08b |
CRP, mg/L | 9.14 ± 7.71 | 7.66 ± 7.08 | 8.83 ± 6.67 | 11.02 ± 9.19 |
DAS-28-based CRP | 3.40 ± 1.30 | 2.90 ± 1.20 | 3.82 ± 1.24 | 3.53 ± 1.36 |
TNFα, pg/Ml | 57.05 ± 39.87 | 62.03 ± 34.40 | 60.93 ± 53.82 | 48.83 ± 27.48 |
sLep, ng/Ml | 119.70 ± 104.64 | 45.98 ± 40.26a | 121.65 ± 106.35 | 188.21 ± 100.88 |
sLepR, ng/Ml | 50.45 ± 17.25 | 60.02 ± 18.81c | 51.34 ± 12.51 | 37.49 ± 9.67 |
sLep/sLepR, ng/mL | 2.87 ± 3.19 | 0.98 ± 1.40a | 2.45 ± 2.45 | 5.67 ± 3.56 |
Insulin resistance, n (%) | 18 (36.7) | 5 (26.3) | 5 (35.7) | 8 (50.0) |